<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28881696</article-id><article-id pub-id-type="pmc">5584297</article-id><article-id pub-id-type="publisher-id">18417</article-id><article-id pub-id-type="doi">10.18632/oncotarget.18417</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Paper</subject></subj-group></article-categories><title-group><article-title>The effect of intraperitoneal chemotherapy on early pain hyperalgesia in patients following elective laparoscopic transabdominal resection of rectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chang-Ying</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Chun-Guang</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zong-Wang</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Zhi-Jian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Pain Management, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China</aff><aff id="A2"><sup>2</sup> Department of Anesthesiology, Liaocheng People&#x02019;s Hospital, Liaocheng, Shandong, P.R. China</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold> Zhi-Jian Fu, <email>179835518@qq.com</email></corresp></author-notes><pub-date pub-type="collection"><day>1</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>8</day><month>6</month><year>2017</year></pub-date><volume>8</volume><issue>31</issue><fpage>51869</fpage><lpage>51877</lpage><history><date date-type="received"><day>3</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Liang et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License 3.0</ext-link> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Chemotherapy has been associated with hyperalgesia. This prospective study was designed to investigate the effect of intraperitoneal chemotherapy with lobaplatin on post-operative pain intensity and sufentanil requirements after laparoscopic transabdominal resection of rectal cancer.</p></sec><sec><title>Methods</title><p>Eighty subjects (40 subjects treated with intraperitoneal chemotherapy and 40 subjects without chemotherapy treatment) scheduled for laparoscopic transabdominal resection of rectal cancer were included in this study. All subjects received standardized anesthetic and patient-controlled analgesia using sufentanil for 72 h post-surgery, as the only analgesics. Pain intensity scores, cumulative sufentanil requirements and side effects were recorded until 72 h post-surgery.</p></sec><sec><title>Results</title><p>Following intraperitoneal chemotherapy, patients had a significantly higher total post-operative sufentanil requirement (193 &#x003bc;g <italic>vs</italic>. 142 &#x003bc;g; <italic>P</italic> = 0.008), significantly higher verbal rating scale post-surgery pain intensity scores at rest and with coughing (<italic>P</italic> &#x0003c; 0.05), and a significantly worse functional activity score (<italic>P</italic> &#x0003c; 0.05) over 72 h, compared with those without intraperitoneal chemotherapy. There were no post-operative differences in the incidence of side-effects (post-operative nausea [<italic>P</italic> = 0.189], vomiting [<italic>P</italic> = 0.311], pruritus [<italic>P</italic> = 0.263], respiratory depression [<italic>P</italic> = 1.000], and dizziness [<italic>P</italic> = 0.712]) between the two groups.</p></sec><sec><title>Conclusion</title><p>Intraperitoneal chemotherapy is associated with significantly increased post-operative sufentanil requirements and pain intensity, suggesting chemotherapy-associated hyperalgesia.</p></sec></abstract><kwd-group><kwd>chemotherapy</kwd><kwd>hyperalgesia</kwd><kwd>lobaplatin</kwd><kwd>colorectal cancer</kwd><kwd>sufentanil</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>BACKGROUND</title><p>It is estimated that 20% to 40% of patients with cancer who receive chemotherapy will develop painful chemotherapy-induced peripheral neuropathy (CIPN), which commonly occurs in patients using taxanes, platinums and vinca alkaloids [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. The symptoms of CIPN are sensory and manifest mainly as hyperalgesia, allodynia, tingling and numbness [<xref rid="R4" ref-type="bibr">4</xref>]. CIPN can persist from months to years beyond chemotherapy completion, significantly reducing the quality of life of cancer patients and the efficacy of chemotherapy [<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R9" ref-type="bibr">9</xref>]. It is difficult to manage, and a variety of drugs with diverse mechanisms have not been effective in treating the condition [<xref rid="R10" ref-type="bibr">10</xref>]. It has been demonstrated that lobaplatin, a third-generation platinum antitumor agent, could significantly inhibit the growth of colorectal carcinoma cells in vitro and induce the apoptosis of LOVO cells [<xref rid="R11" ref-type="bibr">11</xref>]. Previous clinical trials have indicated that lobaplatin has antitumor effects in human solid tumors, such as ovarian cancer, breast cancer and colorectal cancer [<xref rid="R12" ref-type="bibr">12</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref>]. Intraperitoneal chemotherapy (IPC) with lobaplatin has been shown to be a practicable procedure with acceptable safety and can prolong the overall survival of patients with peritoneal carcinomatosis (PC) and in patients with gastrointestinal malignancies [<xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>]. However, lobaplatin therapy-related hyperalgesia following laparoscopic colectomy, a potential for significant post-operative opioid requirement, has not been investigated in a clinical situation. The current study hypothesized that chemotherapy using a single intraperitoneal administration of lobaplatin is associated with increased early postoperative hyperalgesia, as evidenced by a higher post-operative opioid requirement and pain intensity for 72 h after a major surgery.</p></sec><sec sec-type="methods" id="s2"><title>MATERIALS AND METHODS</title><sec id="s2_1"><title>Participants</title><p>Informed consent was obtained from 84 subjects after approval from the Institutional Review Board of Liaocheng People's Hospital. The subjects were recruited preoperatively after a decision to operate made by the Department of General Surgery, during the period January to March, 2017. All subjects presenting for elective laparoscopic transabdominal resection of rectal cancer were included in the data analysis. The inclusion criteria included an American Society of Anesthesiology physical status of I, II or III, age of 46-65 years, and a body mass index less than or equal to 30. The exclusion criteria included contraindications to post-operative patient-controlled analgesia (PCA), an allergy to sufentanil, an allergy to lobaplatin, history of sinus bradycardia or atrioventricular block, history of major psychiatric disorder, history of substance abuse, current opioid use and history of chronic pain. Before surgery, the subjects were instructed in the use of the PCA device, numerical rating scale ([NRS], 0 = no pain, and 10 = worst pain imaginable) and the functional activity score (FAS) for pain assessments. The study was registered at <ext-link ext-link-type="uri" xlink:href="http://chictr.org">chictr.org</ext-link> ( ChiCTR-IOR-17010915 ).</p></sec><sec id="s2_2"><title>Randomization and blinding</title><p>After informed written consent was obtained, a computer-generated randomization table was used to assign the patients into Group L and Group C (n = 40 per group) by an independent anesthetist before the surgery. Before the end of the surgery, a nurse blinded to the study prepared the experimental drug in the preparing room (lobaplatin 100 mg diluted in 500 mL in Groups L or 5% glucose in 500 mL in Group C), and then transferred it to the operation room. After the abdomen was closed, a single i.p. injection of lobaplatin in Group L or 5% glucose in Group C was administered via a drainage tube, and then the drainage tube was clipped for 6 h by the surgeon. The surgeons, anesthetists, nurses and members involved in the acute pain services were blinded to the patient classification.</p></sec><sec id="s2_3"><title>Anesthesia</title><p>None of the patients had received any medication before the induction of anesthesia. At the start of the anesthesia, a peripheral venous access was established in the right upper extremity, and a five-lead electrocardiogram, blood pressure, and oxygen saturation were continuously monitored using an automated system (Philips IntelliVue MP50). All subjects received a standardized general anesthetic using propofol (2.0 mg/kg), fentanyl (3 &#x003bc;g/kg) and nondepolarizing muscle relaxation using cisatracurium (0.15 mg/kg) on induction; then, tracheal intubation was performed 3 min later. During the period of anesthesia, general anesthesia was maintained using inspired sevoflurane at 1.5-2.5% and an i.v. infusion of remifentanil at 1 &#x003bc;g/kg/h to maintain hemodynamic limits (both mean blood pressure and heart rate) between 20% less and 20% more than preoperative levels. An additional 0.03 mg/kg of cisatracurium was administrated every hour from induction up to approximately 1 h prior to the end of operation and a bolus of fentanyl (50 &#x003bc;g) was administered after each additional 30 min of anesthesia. No other analgesics were administered during surgery. The subjects were ventilated at a tidal volume of 10 mL/kg, with the aim of maintaining the end-tidal CO<sub>2</sub> concentration at 30-35 mmHg.</p></sec><sec id="s2_4"><title>Post-operative analgesia</title><p>After surgery, all the patients were transferred to the post-anesthesia care unit. The time of recovery of consciousness was defined as time 0. For 72 h after time 0, all subjects were provided with an i.v. PCA pump (Gemstar, Hospira, Inc., Lake Forest, IL, USA) as the sole analgesic. The PCA pump was programmed to deliver a bolus dose of 1.6 &#x003bc;g of sufentanil (2 mL), with a lockout of 5 min, no background infusion and a 4 h limit of 24 &#x003bc;g of sufentanil (30 mL). The goal of PCA was to maintain the at rest &#x02264;4 post-operatively. Any subject with inadequate analgesia during the 72-h assessment period had the PCA sufentanil bolus increased to 3.2 &#x003bc;g (4 mL). For patients with a poor response to sufentanil, a NRS score of &#x0003e;7 (or NRS with coughing [NRSc]), or the occurrence of an obvious sufentanil-associated adverse effect, supplemental rescue boluses of 1 g of intravenous paracetamol were administered. The patients were monitored for adverse effects. Hypotension or bradycardia was treated using ephedrine or atropine, respectively, while respiratory depression was treated using naloxone and oxygen. The total dose requirements (72 h) for PCA sufentanil were calculated.</p></sec><sec id="s2_5"><title>Post-operative recordings and pain assessments</title><p>The trial was designed only to reach the endpoint of consumption of i.v. PCA sufentanil during the first 72 h after surgery. The secondary outcome measures were the postoperative pain intensity scores, both at rest and with coughing (NRSc), and FAS. Objective pain intensity was assessed using NRS from 0 to 10, where 0 = no pain, 10 = the worst pain imaginable, both at rest and with coughing, at 4, 24, 48 and 72 h after the operation. The FAS is a subjective pain intensity assessment performed by doctors using A, B and C, such that A = not limited: functional activity not limited because of pain, B = mild to moderate limitation: functional activity mildly to moderately limited because of pain, C = severely restricted: functional activity severely limited because of pain. The FAS was also recorded at 4, 24, 48 and 72 h after the operation. The potential side effects of sufentanil were also recorded: nausea, vomiting, pruritus, respiratory depression (defined as a ventilatory frequency of less than eight breaths per minute) and dizziness. Subjects experiencing severe pruritus were offered 0.04-0.1 mg of i.v. naloxone. Any subject who experienced vomiting more than three times a day was treated using i.v. tropisetron (4 mg).</p></sec><sec id="s2_6"><title>Statistical analysis</title><p>Sample size was based on a power calculation, which showed that 35 subjects per group were necessary to achieve 80% power to detect a 20% difference in sufentanil requirement, assuming a significance level of 0.05 [<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R19" ref-type="bibr">19</xref>]. Assuming a dropout rate of 20%, a further 14 subjects were recruited so that each study group would have at least 35 subjects for a complete dataset. Therefore, a sample size of 84 was chosen for adequate data collection.</p><p>The Kolmogorov-Smirnov test was used to assess the distribution of variables. The homogeneity of variance was determined using Levene's tests. Quantitative data are expressed as mean and standard deviation or median and inter-quartile range. Inter-group comparisons were performed using repeated-measures analysis of variance. Categorical data are expressed as frequency and percentage and were analyzed using chi-squared tests or Fisher's exact tests when appropriate. Probability values of P &#x0003c; 0.05 were considered statistically significant. Statistical analysis was performed using SPSS for Windows version 16.0 (SPSS Inc. Chicago, IL, USA).</p></sec></sec><sec id="s3"><title>RESULTS</title><p>The patient flow chart is presented in Figure <xref ref-type="fig" rid="F1">1</xref>. A total of 84 subjects were recruited. Four patients did not complete the study because of PCA malfunction, change of operation method, or surgery cancelation. Therefore, only data concerning the remaining 80 subjects are analyzed in this study. There were no significant differences in the demographic parameters of the two groups. There were also no differences in the duration of surgery and intra-operative medication requirements between the two groups (Table <xref ref-type="table" rid="T1">1</xref>, P&#x0003e;0.05; Table <xref ref-type="table" rid="T2">2</xref>, P&#x0003e;0.05). No subject required a change in analgesic technique. The total post-operative requirement of PCA sufentanil in Group L was significantly more than that in Group C (Figure <xref ref-type="fig" rid="F2">2</xref>, P &#x0003c; 0.05). The NRS pain intensity scores were low in both groups, but the pain intensity scores in the subjects of Group L were significantly higher at rest at 4h, 24h, 48h and 72h (Figure <xref ref-type="fig" rid="F3">3</xref>, P &#x0003c; 0.05) and with coughing at 24h, 48h and 72h (Figure <xref ref-type="fig" rid="F4">4</xref>, P &#x0003c; 0.05). There were significant differences in the FAS between Group L and Group C at 4 h (Table <xref ref-type="table" rid="T3">3</xref>, P &#x0003c; 0.01) and 24 h (Table <xref ref-type="table" rid="T3">3</xref>, P &#x0003c; 0.01), but no significant differences between the two groups at 48 h (Table <xref ref-type="table" rid="T3">3</xref>, P&#x0003e;0.05) and 72 h (Table <xref ref-type="table" rid="T3">3</xref>, P&#x0003e;0.05). Side-effects are presented in Table <xref ref-type="table" rid="T4">4</xref>. There were no significant differences in the post-operative incidence of nausea and vomiting (Table <xref ref-type="table" rid="T4">4</xref>, P&#x0003e;0.05) at 0-72 h between the two groups. There were also no differences in the incidence of pruritus and dizziness between the two groups (Table <xref ref-type="table" rid="T4">4</xref>, P&#x0003e;0.05). No subject experienced respiratory depression in this study (Table <xref ref-type="table" rid="T4">4</xref>, P&#x0003e;0.05). Groups C and L had similar rescue analgesia requirements (Table <xref ref-type="table" rid="T5">5</xref>, P&#x0003e;0.05).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Patient flow chart</title><p>Group C = control group; Group L = treated group. PCA, patient-controlled analgesia.</p></caption><graphic xlink:href="oncotarget-08-51869-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Demographic and perioperative data</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group C (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1">Group L (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Age (yr)</td><td align="center" valign="top" rowspan="1" colspan="1">57.2 &#x000b1; 5.5</td><td align="center" valign="top" rowspan="1" colspan="1">57.6 &#x000b1; 6.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.741</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Male/female (n)</td><td align="center" valign="top" rowspan="1" colspan="1">21/19</td><td align="center" valign="top" rowspan="1" colspan="1">18/22</td><td align="center" valign="top" rowspan="1" colspan="1">0.502</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">67.0 &#x000b1; 6.4</td><td align="center" valign="top" rowspan="1" colspan="1">66.0 &#x000b1; 8.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.569</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">23.9 &#x000b1; 1.5</td><td align="center" valign="top" rowspan="1" colspan="1">23.8 &#x000b1; 2.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.906</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">ASA: I/II/III (n)</td><td align="center" valign="top" rowspan="1" colspan="1">3/32/5</td><td align="center" valign="top" rowspan="1" colspan="1">3/33/4</td><td align="center" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Blood loss (mL)</td><td align="center" valign="top" rowspan="1" colspan="1">138 &#x000b1; 33</td><td align="center" valign="top" rowspan="1" colspan="1">134 &#x000b1; 29</td><td align="center" valign="top" rowspan="1" colspan="1">0.576</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Length of surgery (min)</td><td align="center" valign="top" rowspan="1" colspan="1">169 &#x000b1; 37</td><td align="center" valign="top" rowspan="1" colspan="1">167 &#x000b1; 45</td><td align="center" valign="top" rowspan="1" colspan="1">0.825</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Fluid infusion (mL)</td><td align="center" valign="top" rowspan="1" colspan="1">1468 &#x000b1; 208</td><td align="center" valign="top" rowspan="1" colspan="1">1443 &#x000b1; 273</td><td align="center" valign="top" rowspan="1" colspan="1">0.646</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Urine (mL)</td><td align="center" valign="top" rowspan="1" colspan="1">415 &#x000b1; 124</td><td align="center" valign="top" rowspan="1" colspan="1">442 &#x000b1; 139</td><td align="center" valign="top" rowspan="1" colspan="1">0.376</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#x000b1; standard deviation or number of patients (%); Group C = control group; Group L = treated group; no significant differences were observed (<italic>P</italic> &#x0003e; 0.05). BMI: Body Mass Index; ASA: American Society of Anesthesiology</p></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Anesthetic agents and intraoperative medication</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group C (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1">Group L (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Propofol (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">134 &#x000b1; 13</td><td align="center" valign="top" rowspan="1" colspan="1">132 &#x000b1; 16</td><td align="center" valign="top" rowspan="1" colspan="1">0.569</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Fentanyl (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.343</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Cisatracurium (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">23.7 &#x000b1; 3.0</td><td align="center" valign="top" rowspan="1" colspan="1">22.5 &#x000b1; 2.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.062</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Sevoflurane (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2.5 &#x000b1; 0.4</td><td align="center" valign="top" rowspan="1" colspan="1">2.4 &#x000b1; 0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.623</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Remifentanyl (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7 &#x000b1; 0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.7 &#x000b1; 0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.976</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Atropine (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (10%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.737</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Ephedrine (mg)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (20%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (15%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.556</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#x000b1; standard deviation or number of patients (%); Group C = control group; Group L = treated group; no significant differences were observed (<italic>P</italic> &#x0003e; 0.05).</p></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Sufentanil dosage during 72 h after surgery in Group C and Group L</title><p>Continuous variables are presented as mean &#x000b1; standard deviation. Group C = control group; Group L = treated group; *<italic>P</italic> &#x0003c; 0.05 <italic>vs</italic> Group C, **<italic>P</italic> &#x0003c; 0.01 <italic>vs</italic> Group C.</p></caption><graphic xlink:href="oncotarget-08-51869-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Pain score (NRS) at rest during 72 h after surgery in Group C and Group L</title><p>Variables are presented as median (interquartile range). Group C = control group; Group L = treated group; *<italic>P</italic> &#x0003c; 0.05 <italic>vs</italic> Group C, **<italic>P</italic> &#x0003c; 0.01 <italic>vs</italic> Group C. NRS = numerical rating scale.</p></caption><graphic xlink:href="oncotarget-08-51869-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Pain score (NRS) with coughing during 72 h after surgery in Group C and Group L</title><p>Variables are presented as median (interquartile range). Group C = control group; Group L = treated group; *<italic>P</italic> &#x0003c; 0.05 <italic>vs</italic> Group C, **<italic>P</italic> &#x0003c; 0.01 <italic>vs</italic> Group C. NRS = numerical rating scale.</p></caption><graphic xlink:href="oncotarget-08-51869-g004"/></fig><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Functional activity score</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group C</th><th align="center" valign="top" rowspan="1" colspan="1">Group L</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="4" align="left" valign="top" colspan="1">FAS:<break/>C/B/A (n)</td><td align="center" valign="top" rowspan="1" colspan="1">4 h</td><td align="center" valign="top" rowspan="1" colspan="1">26/8/6</td><td align="center" valign="top" rowspan="1" colspan="1">39/0/1</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001**</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">24 h</td><td align="center" valign="top" rowspan="1" colspan="1">0/1/39</td><td align="center" valign="top" rowspan="1" colspan="1">0/9/31</td><td align="center" valign="top" rowspan="1" colspan="1">0.007**</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">48 h</td><td align="center" valign="top" rowspan="1" colspan="1">0/0/40</td><td align="center" valign="top" rowspan="1" colspan="1">0/3/37</td><td align="center" valign="top" rowspan="1" colspan="1">0.120</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">72 h</td><td align="center" valign="top" rowspan="1" colspan="1">0/0/40</td><td align="center" valign="top" rowspan="1" colspan="1">0/2/38</td><td align="center" valign="top" rowspan="1" colspan="1">0.494</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number of patients (%); Group C = control group; Group L = treated group; *<italic>P</italic> &#x0003c; 0.05 <italic>vs</italic> Group C, **<italic>P</italic> &#x0003c; 0.01 <italic>vs</italic> Group C.A = not limited: functional activity not limited because of pain, B = mild to moderate limitation: functional activity mildly to moderately limited because of pain, C = severely restricted: functional activity severely limited because of pain.</p></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Side effects</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group C (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1">Group L (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">Nausea, n(%)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.189</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Vomiting, n(%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.311</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Pruritus, n(%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.263</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Respiratory depression, n(%)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Dizziness, n(%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (12.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.712</td></tr></tbody></table><table-wrap-foot><p>Data are presented as number of patients (%); Group C = control group; Group L = treated group; no significant differences were observed (<italic>P</italic> &#x0003e; 0.05).</p></table-wrap-foot></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Rescue analgesia</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Group C (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1">Group L (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">n (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.154</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#x000b1; standard deviation or number of patients (%); Group C = control group; Group L = treated group; no significant differences were observed (<italic>P</italic> &#x0003e; 0.05).</p></table-wrap-foot></table-wrap></sec><sec id="s4"><title>DISCUSSION</title><p>The current study is the first clinical study that describes increased post-operative opioid requirements and pain intensity in subjects following intraperitoneal chemotherapy with lobaplatin, with no significant difference in the incidence post-operative nausea and vomiting, pruritus, respiratory depression and dizziness.</p><p>CIPN is a potentially dose-limiting side-effect, commonly observed after application of various chemotherapeutic drugs including taxanes, vinca alkaloids, platinum compounds, bortezomib and thalidomide [<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]. It is painful and/or disabling, causing a significant loss of functional abilities and decreasing quality of life reversibly or permanently. To date, many preventive and treatment strategies have been explored without significant efficacy. Most patients develop symptoms during, or soon after, chemotherapy administration, and in some patients it is associated with the first dose [<xref rid="R20" ref-type="bibr">20</xref>]. IPC has been demonstrated to be effective in clinical studies, and it could prolong overall survival in colorectal PC patients [<xref rid="R21" ref-type="bibr">21</xref>]. A prospective pilot study found that abdominal pain was the most common secondary effect in patients following IPC [<xref rid="R22" ref-type="bibr">22</xref>]. Moreover, some studies have demonstrated increased pain intensity early after IPC [<xref rid="R23" ref-type="bibr">23</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>]. It has also been reported that 45% of patients undergoing IPC for PC using oxaliplatin displayed significant pain and limitations in terms of physical function after the treatment [<xref rid="R26" ref-type="bibr">26</xref>]. C. Schmidt and M. Creutzenberg retrospectively reviewed 78 patients, and found that postoperative consumption of epidural ropivacaine was a median of 5.0 g (0.8-11.2 g), and for piritramide a median of 210 mg (105-639 mg), after cytoreductive surgery using hyperthermic IPC [<xref rid="R27" ref-type="bibr">27</xref>]. Previous animal studies have revealed that a single intraperitoneal administration of oxaliplatin could decrease the mechanical threshold and induce mechanical allodynia, and the decreased threshold remained for 7 d after the treatment [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R29" ref-type="bibr">29</xref>].</p><p>This is consistent with the findings of the current study, in which an increased requirement for postoperative opioids was observed among subjects following IPC. The exact underlying mechanisms of some anti-cancer drugs have only recently begun to be understood. Dorsal root ganglia are considered to be the primary target of Pt drugs, where they cause apoptosis of sensory neurons and DNA damage [<xref rid="R30" ref-type="bibr">30</xref>]. The mechanisms underlying hyperalgesia following a single intraperitoneal administration of chemotherapeutic may be as follows. (1) The sensitization of A&#x003b2; - and C-fibers may contribute to the development of hyperalgesia induced by anticancer drugs, as demonstrated in rats [<xref rid="R31" ref-type="bibr">31</xref>]. (2) The concentration of anticancer drugs in the cerebrospinal fluid increases gradually after a single intraperitoneal administration, which may significantly increase the field potentials in the dorsal horn, eventually inducing hyperalgesia [<xref rid="R32" ref-type="bibr">32</xref>]. (3) Kim HK reported that oxidative stress and inflammatory processes might be involved in the development of CIPN through animal studies [<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>]. (4) Another reason for hyperalgesia is that persistent visceral pain is always accompanied by hyperalgesia of the skin and internal organs [<xref rid="R35" ref-type="bibr">35</xref>].</p><p>Despite the strong evidence for chemotherapy-induced mechanical hyperalgesia, clinical prospective studies to date have yielded varying analgesic requirement patterns. The main reason for this is that human studies rely on the subjective responses of patients to assess pain. Moreover, humans have more control in experimental pain studies, compared with experimental animals in animal studies, and can choose not to participate at all or withdraw at any point during the study. In consideration of the subjectivity of NRS, we used FAS, a three-level scoring method recommended by the Victorian Quality Council to assess pain intensity, as an objective pain intensity assessment method. The FAS is a reliable and valid method, and is suitable for assessing dynamic pain in postoperative patients. It was observed that there were significant differences in the FAS between Group L and Group C at 4 h and 24 h, but no significant difference between Group L and Group C at 48 h and 72 h, indicating that IPC using lobaplatin could induce hyperalgesia in cancer patients.</p><p>Nausea and vomiting are common complaints after general anesthesia, with a multifactorial etiology. The risk factors for increased post-operative nausea and vomiting include younger age, female gender, prior history of dizziness, a higher requirement for perioperative opioids, a longer duration of anesthesia and specific types of surgery, such as laparoscopic surgery [<xref rid="R36" ref-type="bibr">36</xref>]. The incidence of nausea and vomiting did not differ significantly between the two groups. In the current study, the sufentanil requirement was higher in subjects following IPC, but the incidence of nausea and vomiting was similar. The incidence of pruritus, respiratory depression and dizziness, all known as adverse effects of sufentanil, was not significantly different between Group C and Group L.</p><p>The current study has some limitations. Firstly, it is a clinical study which provides few clues about the mechanisms of chemotherapy-induced hyperalgesia and only describes an increased opioid requirement and pain severity. Secondly, pain is an objective sensory phenomenon, and its intensity is associated with age, gender, psychological status and life experiences. The current study does not consider those factors, which may have affected the results. Finally, the current study was performed at a single center. Investigations of more diverse populations from different centers and the use of different surgical techniques would furnish more conclusive results.</p><p>In conclusion, IPC using lobaplatin was found to be associated with increased sufentanil requirements, an increased NRS and a worse FAS within the initial 72 hours after elective laparoscopic transabdominal resection of rectal cancer, compared with subjects who were not treated using lobaplatin. Future studies could explore the mechanisms underlying IPC-mediated lobaplatin-induced hyperalgesia in a clinical setting. A longer term follow-up of patients following IPC, to compare rates of chronic post-surgical pain, would also be potentially beneficial.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Min Liang and Zhi-Jian Fu conceived and designed the trail; Chang-Ying Li and Zong-Wang Zhang collected the data; Chun-Guang Ren and Min Liang analyzed the data; Min Liang, Chang-Ying Li and Zhi-Jian Fu wrote the article.</p></fn></fn-group><ack><p>The authors would like to thank Dr. Daogui Yang for the help in implementing the clinical trial.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICT OF INTEREST</bold></p><p>The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This study was supported by grants from the National Natural Science Foundation of China (81471134) and the Natural Science Foundation of Shandong Province (ZR2016HB28).</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>CIPN</term><def><p>chemotherapy-induced peripheral neuropathy</p></def></def-item><def-item><term>IPC</term><def><p>Intraperitoneal chemotherapy</p></def></def-item><def-item><term>PC</term><def><p>peritoneal carcinomatosis</p></def></def-item><def-item><term>PCA</term><def><p>patient-controlled analgesia</p></def></def-item><def-item><term>ASA</term><def><p>American Society of Anesthesiology</p></def></def-item><def-item><term>NRS</term><def><p>numerical rating scale</p></def></def-item><def-item><term>FAS</term><def><p>functional activity score</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautio</surname><given-names>AL</given-names></name><name><surname>Haanp&#x000e4;&#x000e4;</surname><given-names>M</given-names></name><name><surname>Kautiainen</surname><given-names>H</given-names></name><name><surname>Kalso</surname><given-names>E</given-names></name><name><surname>Saarto</surname><given-names>T</given-names></name></person-group><article-title>Burden of chemotherapy-induced neuropathy-a cross-sectional study</article-title><source>Support Care Cancer</source><year>2011</year><volume>19</volume><fpage>1991</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21080201</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Pett</surname><given-names>MA</given-names></name><name><surname>Beck</surname><given-names>SL</given-names></name></person-group><article-title>The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums</article-title><source>Cancer Nurs</source><year>2010</year><volume>33</volume><fpage>173</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">20357656</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loprinzi</surname><given-names>CL</given-names></name><name><surname>Reeves</surname><given-names>BN</given-names></name><name><surname>Dakhil</surname><given-names>SR</given-names></name><name><surname>Sloan</surname><given-names>JA</given-names></name><name><surname>Wolf</surname><given-names>SL</given-names></name><name><surname>Burger</surname><given-names>KN</given-names></name><name><surname>Kamal</surname><given-names>A</given-names></name><name><surname>Le-Lindqwister</surname><given-names>NA</given-names></name><name><surname>Soori</surname><given-names>GS</given-names></name><name><surname>Jaslowski</surname><given-names>AJ</given-names></name><name><surname>Novotny</surname><given-names>PJ</given-names></name><name><surname>Lachance</surname><given-names>DH</given-names></name></person-group><article-title>Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1472</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21383290</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quasthoff</surname><given-names>S</given-names></name><name><surname>Hartung</surname><given-names>HP</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neuropathy</article-title><source>J Neurol</source><year>2002</year><volume>249</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">11954874</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>EM</given-names></name><name><surname>Bakitas</surname><given-names>MA</given-names></name><name><surname>Homel</surname><given-names>P</given-names></name><name><surname>Piehl</surname><given-names>M</given-names></name><name><surname>Kingman</surname><given-names>L</given-names></name><name><surname>Fadul</surname><given-names>CE</given-names></name><name><surname>Bookbinder</surname><given-names>M</given-names></name></person-group><article-title>Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer</article-title><source>J Pain Symptom Manage</source><year>2011</year><volume>42</volume><fpage>822</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">21820851</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakitas</surname><given-names>MA</given-names></name></person-group><article-title>Background noise: the experience of chemotherapy-induced peripheral neuropathy</article-title><source>Nurs Res</source><year>2007</year><volume>56</volume><fpage>323</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17846553</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimozuma</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Aranishi</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Kuroi</surname><given-names>K</given-names></name><name><surname>Ohsumi</surname><given-names>S</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name><name><surname>Katsumata</surname><given-names>N</given-names></name><name><surname>Kuranami</surname><given-names>M</given-names></name><name><surname>Suemasu</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Hausheer</surname><given-names>FH</given-names></name></person-group><article-title>Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><fpage>3355</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22584733</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>MJ</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Cooper</surname><given-names>BA</given-names></name><name><surname>Miaskowski</surname><given-names>C</given-names></name></person-group><article-title>The effect of symptom clusters on functional status and quality of life in women with breast cancer</article-title><source>Eur J Oncol Nurs</source><year>2010</year><volume>14</volume><fpage>101</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19897417</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tofthagen</surname><given-names>C</given-names></name></person-group><article-title>Surviving chemotherapy for colon cancer and living with the consequences</article-title><source>J Palliat Med</source><year>2010</year><volume>13</volume><fpage>1389</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">21091028</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubblefield</surname><given-names>MD</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><name><surname>Burton</surname><given-names>AW</given-names></name><name><surname>Custodio</surname><given-names>CM</given-names></name><name><surname>Deng</surname><given-names>GE</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Junck</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>GS</given-names></name><name><surname>Paice</surname><given-names>JA</given-names></name><name><surname>Tummala</surname><given-names>S</given-names></name><name><surname>Von Roenn</surname><given-names>JH</given-names></name></person-group><article-title>NCCN task force report: management of neuropathy in cancer</article-title><source>J Natl Compr Canc Netw</source><year>2009</year><volume>7</volume><fpage>S1</fpage><lpage>26</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>XL</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>XY</given-names></name><name><surname>Xiao</surname><given-names>XY</given-names></name></person-group><article-title>Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>17426</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">25516654</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Lou</surname><given-names>LG</given-names></name><name><surname>Sui</surname><given-names>DH</given-names></name><name><surname>Wu</surname><given-names>XH</given-names></name></person-group><article-title>Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells</article-title><source>Asian Pac J Cancer Prev</source><year>2014</year><volume>15</volume><fpage>9939</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25520132</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>QQ</given-names></name><name><surname>Huang</surname><given-names>XE</given-names></name><name><surname>Ye</surname><given-names>LH</given-names></name><name><surname>Lu</surname><given-names>YY</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name></person-group><article-title>Phase II trial of Loubo&#x000ae; (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes</article-title><source>Asian Pac J Cancer Prev</source><year>2013</year><volume>14</volume><fpage>413</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23534764</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>SK</given-names></name><name><surname>He</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name></person-group><article-title>Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro</article-title><source>Biomed Pharmacother</source><year>2011</year><volume>65</volume><fpage>137</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21612887</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HT</given-names></name><name><surname>Peng</surname><given-names>KW</given-names></name><name><surname>Ji</surname><given-names>ZH</given-names></name><name><surname>Sun</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Huang</surname><given-names>CQ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: results from a Chinese center</article-title><source>Eur J Surg Oncol</source><year>2016</year><volume>42</volume><fpage>1024</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">27179924</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>[Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers]. [Article in Chinese]</article-title><source>Zhonghua Wei Chang Wai Ke Za Zhi</source><year>2015</year><volume>18</volume><fpage>1006</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26499146</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HT</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Huang</surname><given-names>CQ</given-names></name><name><surname>Sun</surname><given-names>JH</given-names></name><name><surname>Ji</surname><given-names>ZH</given-names></name><name><surname>Peng</surname><given-names>KW</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies</article-title><source>World J Surg Oncol</source><year>2016</year><volume>14</volume><fpage>246</fpage><pub-id pub-id-type="pmid">27633880</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Chi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Dexmedetomidine in Postoperative Analgesia in Patients Undergoing Hysterectomy: A CONSORT-Prospective, Randomized, Controlled Trial</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e1348</fpage><pub-id pub-id-type="pmid">26266386</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name></person-group><article-title>Effect of Intraoperative and Postoperative Infusion of Dexmedetomidine on the Quality of Postoperative Analgesia in Highly Nicotine-Dependent Patients After Thoracic Surgery: A CONSORT-Prospective, Randomized, Controlled Trial</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e1329</fpage><pub-id pub-id-type="pmid">26266376</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuse</surname><given-names>N</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Taku</surname><given-names>K</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Muto</surname><given-names>M</given-names></name><name><surname>Asaka</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><article-title>Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer</article-title><source>Jpn J Clin Oncol</source><year>2007</year><volume>37</volume><fpage>434</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17656481</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>EK</given-names></name><name><surname>Choudhury</surname><given-names>RA</given-names></name><name><surname>Roses</surname><given-names>RE</given-names></name><name><surname>Fraker</surname><given-names>DL</given-names></name><name><surname>Kelz</surname><given-names>RR</given-names></name><name><surname>Karakousis</surname><given-names>GC</given-names></name></person-group><article-title>Intraperitoneal chemotherapy at the time of surgery is not associated with increased 30-day morbidity and mortality following colorectal resection</article-title><source>Ann Surg Oncol</source><year>2015</year><volume>22</volume><fpage>1664</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">25124471</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Casares</surname><given-names>FC</given-names></name><name><surname>Rufi&#x000e1;n</surname><given-names>S</given-names></name><name><surname>Arjona-S&#x000e1;nchez</surname><given-names>&#x000c1;</given-names></name><name><surname>Rubio</surname><given-names>MJ</given-names></name><name><surname>D&#x000ed;az</surname><given-names>R</given-names></name><name><surname>Casado</surname><given-names>&#x000c1;</given-names></name><name><surname>Naranjo</surname><given-names>&#x000c1;</given-names></name><name><surname>D&#x000ed;az-Iglesias</surname><given-names>CJ</given-names></name><name><surname>Ortega</surname><given-names>R</given-names></name><name><surname>Mu&#x000f1;oz-Villanueva</surname><given-names>MC</given-names></name><name><surname>Muntan&#x000e9;</surname><given-names>J</given-names></name><name><surname>Aranda</surname><given-names>E</given-names></name></person-group><article-title>Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study</article-title><source>Cancer Chemother Pharmacol</source><year>2011</year><volume>68</volume><fpage>267</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21499894</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodson</surname><given-names>RM</given-names></name><name><surname>McQuellon</surname><given-names>RP</given-names></name><name><surname>Mogal</surname><given-names>HD</given-names></name><name><surname>Duckworth</surname><given-names>KE</given-names></name><name><surname>Russell</surname><given-names>GB</given-names></name><name><surname>Votanopoulos</surname><given-names>KI</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Levine</surname><given-names>EA</given-names></name></person-group><article-title>Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><fpage>772</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">27638671</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>AR</given-names></name><name><surname>McQuellon</surname><given-names>RP</given-names></name><name><surname>Russell</surname><given-names>GB</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Stewart</surname><given-names>JH</given-names><suffix>4th</suffix></name><name><surname>Levine</surname><given-names>EA</given-names></name></person-group><article-title>Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><fpage>3673</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21674272</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albertsmeier</surname><given-names>M</given-names></name><name><surname>Hauer</surname><given-names>A</given-names></name><name><surname>Niess</surname><given-names>H</given-names></name><name><surname>Werner</surname><given-names>J</given-names></name><name><surname>Graeb</surname><given-names>C</given-names></name><name><surname>Angele</surname><given-names>MK</given-names></name></person-group><article-title>Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)</article-title><source>Dig Surg</source><year>2014</year><volume>31</volume><fpage>334</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">25471828</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Tordjmann</surname><given-names>D</given-names></name><name><surname>Gornet</surname><given-names>JM</given-names></name><name><surname>Nemeth</surname><given-names>J</given-names></name><name><surname>Valleur</surname><given-names>P</given-names></name><name><surname>Pocard</surname><given-names>M</given-names></name></person-group><article-title>[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis]. [Article in French]</article-title><source>Bull Cancer</source><year>2010</year><volume>97</volume><fpage>1053</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20693116</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Creutzenberg</surname><given-names>M</given-names></name><name><surname>Piso</surname><given-names>P</given-names></name><name><surname>Hobbhahn</surname><given-names>J</given-names></name><name><surname>Bucher</surname><given-names>M</given-names></name></person-group><article-title>Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy</article-title><source>Anaesthesia</source><year>2008</year><volume>63</volume><fpage>389</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">18336490</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>EK</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name></person-group><article-title>Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat</article-title><source>J Pain</source><year>2009</year><volume>10</volume><fpage>534</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19231296</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>JH</given-names></name><name><surname>Yoon</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Oh</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Beitz</surname><given-names>AJ</given-names></name><name><surname>Roh</surname><given-names>DH</given-names></name></person-group><article-title>Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension</article-title><source>Int J Cancer</source><year>2016</year><volume>138</volume><fpage>2466</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">26704560</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DT</given-names></name><name><surname>Kiernan</surname><given-names>JA</given-names></name></person-group><article-title>Permeation of proteins from the blood into peripheral nerves and ganglia</article-title><source>Neuroscience</source><year>1994</year><volume>59</volume><fpage>755</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8008217</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Kume</surname><given-names>K</given-names></name><name><surname>Ohsawa</surname><given-names>M</given-names></name></person-group><article-title>Oxaliplatin treatment changes the function of sensory nerves in rats</article-title><source>J Pharmacol Sci</source><year>2016</year><volume>130</volume><fpage>189</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">26790975</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZZ</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Ou-Yang</surname><given-names>HD</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xin</surname><given-names>WJ</given-names></name></person-group><article-title>Cerebrospinal Fluid Oxaliplatin Contributes to the Acute Pain Induced by Systemic Administration of Oxaliplatin</article-title><source>Anesthesiology</source><year>2016</year><volume>124</volume><fpage>1109</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">26978408</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SO</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Abdi</surname><given-names>S</given-names></name></person-group><article-title>Pentoxifylline Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain</article-title><source>Pain Physician</source><year>2016</year><volume>19</volume><fpage>589</fpage><lpage>600</lpage></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Abdi</surname><given-names>S</given-names></name></person-group><article-title>Tempol Ameliorates and Prevents Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain</article-title><source>Front Pharmacol</source><year>2017</year><volume>7</volume><fpage>532</fpage><pub-id pub-id-type="pmid">28138318</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blichfeldt-Eckhardt</surname><given-names>MR</given-names></name><name><surname>Ording</surname><given-names>H</given-names></name><name><surname>Andersen</surname><given-names>C</given-names></name><name><surname>Licht</surname><given-names>PB</given-names></name><name><surname>Toft</surname><given-names>P</given-names></name></person-group><article-title>Early visceral pain predicts chronic pain after laparoscopic cholecystectomy</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>2400</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25250720</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;sch</surname><given-names>D</given-names></name><name><surname>Eberhart</surname><given-names>LH</given-names></name><name><surname>Wallenborn</surname><given-names>J</given-names></name><name><surname>Kranke</surname><given-names>P</given-names></name></person-group><article-title>Nausea and vomiting after surgery under general anesthesia: an evidence-based review concerning risk assessment, prevention, and treatment</article-title><source>Dtsch Arztebl Int</source><year>2010</year><volume>107</volume><fpage>733</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21079721</pub-id></element-citation></ref></ref-list></back></article>